EA201290383A1 - Производные пиридинопиридонов, их получение и применение в терапии - Google Patents
Производные пиридинопиридонов, их получение и применение в терапииInfo
- Publication number
- EA201290383A1 EA201290383A1 EA201290383A EA201290383A EA201290383A1 EA 201290383 A1 EA201290383 A1 EA 201290383A1 EA 201290383 A EA201290383 A EA 201290383A EA 201290383 A EA201290383 A EA 201290383A EA 201290383 A1 EA201290383 A1 EA 201290383A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cycle
- atom
- alkyl
- therapy
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Изобретение относится (i) к производным пиридинопиридонов, соответствующим формуле (I), где Rпредставляет собой атом водорода или (C-C)алкил; Rпредставляет собой -(СН)-B, где n'=0, 1, 2, 3 или 4, а В представляет собой (C-C)циклоалкил, (C-C)алкил или (C-C)алкоксигруппу; Y, Z, V и W независимо друг от друга обозначают -СН-, атом углерода, гетероатом или отсутствие атома; при условии, что цикл, в котором содержатся V, W, Y и Z, представляет собой цикл, содержащий 5 или 6 членов, при условии, что пунктирные линии в данном цикле указывают на то, что образующийся цикл представляет собой ароматический цикл, и при условии, что данный цикл содержит 0, 1 или 2 гетероатома; Rи Rнезависимо друг от друга представляют собой одинаковые или разные группы, выбранные из атомов водорода и линейных (C-C)алкилов, или совместно с атомом углерода, с которым они связаны, образуют (C-С)циклоалкил; m обозначает целое число, равное 1, 2, 3 или 4; Rпредставляет собой атом водорода или (C-C)алкил, Rпредставляет собой -(СН)-L, где n=0, 1, 2 или 3, a L обозначает группу, выбранную из арилов, содержащих 6 атомов углерода, 5- или 6-членных гетероарилов, насыщенных гетероциклов, содержащих 5, 6 или 7 членов, или совместно с атомом азота, с которым они связаны, образуют гетероцикл; (ii) к их получению и (iii) к их применению в терапии в качестве ингибиторов киназной активности рецепторов лигандов PDGF и/или рецепторов лиганда FLT3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0905602A FR2952934B1 (fr) | 2009-11-23 | 2009-11-23 | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| PCT/FR2010/052480 WO2011061458A1 (fr) | 2009-11-23 | 2010-11-22 | Dérivés de pyridino-pyridinones, leur préparation et leur application en thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201290383A1 true EA201290383A1 (ru) | 2013-01-30 |
Family
ID=42133583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290383A EA201290383A1 (ru) | 2009-11-23 | 2010-11-22 | Производные пиридинопиридонов, их получение и применение в терапии |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8623893B2 (ru) |
| EP (1) | EP2504338B1 (ru) |
| JP (1) | JP2013511501A (ru) |
| KR (1) | KR20120099732A (ru) |
| CN (1) | CN102762558A (ru) |
| AR (1) | AR079077A1 (ru) |
| AU (1) | AU2010320692A1 (ru) |
| BR (1) | BR112012012403A2 (ru) |
| CA (1) | CA2781935A1 (ru) |
| CL (1) | CL2012001322A1 (ru) |
| CO (1) | CO6481011A2 (ru) |
| CR (1) | CR20120261A (ru) |
| DO (1) | DOP2012000136A (ru) |
| EA (1) | EA201290383A1 (ru) |
| EC (1) | ECSP12011916A (ru) |
| FR (1) | FR2952934B1 (ru) |
| GT (1) | GT201200154A (ru) |
| IL (1) | IL219888A0 (ru) |
| MA (1) | MA33819B1 (ru) |
| MX (1) | MX2012005988A (ru) |
| NI (1) | NI201200095A (ru) |
| NZ (1) | NZ600108A (ru) |
| PE (1) | PE20121338A1 (ru) |
| TN (1) | TN2012000229A1 (ru) |
| TW (1) | TWI476197B (ru) |
| UY (1) | UY33049A (ru) |
| WO (1) | WO2011061458A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| MA37821A1 (fr) * | 2012-07-17 | 2018-02-28 | Sanofi Sa | Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| WO2018053446A1 (en) * | 2016-09-18 | 2018-03-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Yap1 inhibitors that target the interaction of yap1 with oct4 |
| WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
| JP7319977B2 (ja) * | 2017-12-06 | 2023-08-02 | リン バイオサイエンス，インコーポレイテッド | チューブリン阻害剤 |
| BR112020018642A2 (pt) | 2018-03-14 | 2020-12-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Composto da fórmula i, composição farmacêutica, método de tratamento de câncer em um sujeito em necessidade, método de eliminação de uma célula tumoral em um sujeito |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
| US5994367A (en) * | 1997-03-07 | 1999-11-30 | The University Of North Carolina At Chapel Hill | Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| JP3739916B2 (ja) * | 1997-12-02 | 2006-01-25 | 第一製薬株式会社 | サイトカイン産生阻害剤 |
| DE60205899T2 (de) * | 2001-05-24 | 2006-06-29 | Merck Frosst Canada & Co, Kirkland | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| EP1565187A4 (en) * | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | CANCER TREATMENT METHODS AND RELATED METHODS |
| US20080234263A1 (en) | 2003-09-16 | 2008-09-25 | Laurent Francois Andre Hennequin | Quinazoline Derivatives |
| GB0321621D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005091857A2 (en) * | 2004-03-12 | 2005-10-06 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
| WO2007113548A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
| WO2007113565A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| JP2010506879A (ja) * | 2006-10-16 | 2010-03-04 | ノバルティス アーゲー | プロテインキナーゼ阻害剤として有用なフェニルアセトアミド |
| CN101679422A (zh) * | 2007-03-28 | 2010-03-24 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
| FR2917412B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2917413B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2933700B1 (fr) * | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2954943B1 (fr) | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
-
2009
- 2009-11-23 FR FR0905602A patent/FR2952934B1/fr not_active Expired - Fee Related
-
2010
- 2010-11-19 AR ARP100104280A patent/AR079077A1/es unknown
- 2010-11-22 EA EA201290383A patent/EA201290383A1/ru unknown
- 2010-11-22 NZ NZ600108A patent/NZ600108A/xx not_active IP Right Cessation
- 2010-11-22 CN CN2010800621312A patent/CN102762558A/zh active Pending
- 2010-11-22 EP EP10799090.5A patent/EP2504338B1/fr not_active Not-in-force
- 2010-11-22 WO PCT/FR2010/052480 patent/WO2011061458A1/fr active Application Filing
- 2010-11-22 AU AU2010320692A patent/AU2010320692A1/en not_active Abandoned
- 2010-11-22 MX MX2012005988A patent/MX2012005988A/es active IP Right Grant
- 2010-11-22 BR BR112012012403A patent/BR112012012403A2/pt not_active IP Right Cessation
- 2010-11-22 PE PE2012000710A patent/PE20121338A1/es not_active Application Discontinuation
- 2010-11-22 TW TW099140242A patent/TWI476197B/zh not_active IP Right Cessation
- 2010-11-22 KR KR1020127016232A patent/KR20120099732A/ko not_active Application Discontinuation
- 2010-11-22 CA CA2781935A patent/CA2781935A1/fr not_active Abandoned
- 2010-11-22 JP JP2012539393A patent/JP2013511501A/ja active Pending
- 2010-11-23 UY UY0001033049A patent/UY33049A/es not_active Application Discontinuation
-
2012
- 2012-05-15 DO DO2012000136A patent/DOP2012000136A/es unknown
- 2012-05-17 TN TNP2012000229A patent/TN2012000229A1/fr unknown
- 2012-05-18 GT GT201200154A patent/GT201200154A/es unknown
- 2012-05-20 IL IL219888A patent/IL219888A0/en unknown
- 2012-05-21 EC ECSP12011916 patent/ECSP12011916A/es unknown
- 2012-05-21 CR CR20120261A patent/CR20120261A/es unknown
- 2012-05-22 NI NI201200095A patent/NI201200095A/es unknown
- 2012-05-22 US US13/477,778 patent/US8623893B2/en active Active
- 2012-05-23 CL CL2012001322A patent/CL2012001322A1/es unknown
- 2012-05-23 CO CO12084563A patent/CO6481011A2/es not_active Application Discontinuation
- 2012-06-14 MA MA34962A patent/MA33819B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2012001322A1 (es) | 2012-08-17 |
| ECSP12011916A (es) | 2012-07-31 |
| US8623893B2 (en) | 2014-01-07 |
| WO2011061458A1 (fr) | 2011-05-26 |
| CO6481011A2 (es) | 2012-07-16 |
| TWI476197B (zh) | 2015-03-11 |
| TN2012000229A1 (fr) | 2013-12-12 |
| MA33819B1 (fr) | 2012-12-03 |
| AU2010320692A1 (en) | 2012-06-14 |
| UY33049A (es) | 2011-06-30 |
| JP2013511501A (ja) | 2013-04-04 |
| BR112012012403A2 (pt) | 2017-10-10 |
| FR2952934A1 (fr) | 2011-05-27 |
| AR079077A1 (es) | 2011-12-21 |
| MX2012005988A (es) | 2012-09-07 |
| KR20120099732A (ko) | 2012-09-11 |
| US20130005724A1 (en) | 2013-01-03 |
| NI201200095A (es) | 2012-08-20 |
| CN102762558A (zh) | 2012-10-31 |
| CR20120261A (es) | 2012-07-04 |
| IL219888A0 (en) | 2012-07-31 |
| EP2504338A1 (fr) | 2012-10-03 |
| TW201121971A (en) | 2011-07-01 |
| NZ600108A (en) | 2013-06-28 |
| DOP2012000136A (es) | 2012-08-15 |
| CA2781935A1 (fr) | 2011-05-26 |
| GT201200154A (es) | 2013-11-07 |
| EP2504338B1 (fr) | 2015-03-18 |
| FR2952934B1 (fr) | 2012-06-22 |
| PE20121338A1 (es) | 2012-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290383A1 (ru) | Производные пиридинопиридонов, их получение и применение в терапии | |
| CY1118526T1 (el) | Παραγωγα διϋδροπυραζολοπυριμιδινονης | |
| TW200613297A (en) | Pyrazole derivatives | |
| NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
| TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| EA201070782A1 (ru) | Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip) | |
| MY150229A (en) | Stat3/5 activation inhibitor | |
| MX2012002059A (es) | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| EA201390877A1 (ru) | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение | |
| RU2011135977A (ru) | Производное n-ацилантраниловой кислоты или его соль | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
| RU2016139352A (ru) | Способ получения [(3-гидроксипиридин-2-карбонил)амино]алкановых кислот, сложных эфиров и амидов | |
| WO2011085015A3 (en) | Skin lightening compositions | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| BR112017006093A2 (pt) | moduladores alostéricos negativos de n-alquilaril-5-oxiaril-octa-hidro-ciclopenta[c] pirrol de nr2b | |
| EA200802052A1 (ru) | 2-(пиридин-2-ил)-пиримидины в качестве фунгицидов | |
| CR10722A (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| MY161134A (en) | Piperazine compound having a pgds inhibitory effect | |
| EA201692189A1 (ru) | Соединения фосфина золота (i) в качестве антибактериальных агентов |